SCHEMBL13290954

SCHEMBL13290954

CN1CCN(C(=O)[C@H]2CC[C@H](C(=O)Nc3c(C(=O)Nc4ccc(Cl)cn4)oc4cccnc34)CC2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ F10 P00742 7/20 0.44
▸ HPGD P15428 1/20 0.42
▸ GSK3B P49841 3/20 0.42
▸ DYRK1A Q13627 3/20 0.42
▸ WNT1 P04628 1/20 0.42
▸ RAB9A P51151 3/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ TP53 P04637 3/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ TSHR P16473 3/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ NFKB1 P19838 1/20 0.39
▸ NFKB2 Q00653 1/20 0.39
▸ RELA Q04206 1/20 0.39
▸ DEGS1 O15121 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2945028 0.93 SMN1; SMN2 (0.46) SMN1; SMN2F10HPGDRAB9AMAPK1
SCHEMBL2945024 0.93 SMN1; SMN2 (0.46) SMN1; SMN2F10HPGDRAB9AMAPK1
SCHEMBL13290769 0.91 SMN1; SMN2 (0.44) SMN1; SMN2F10RAB9AMAPK1TP53
SCHEMBL13290955 0.90 SMN1; SMN2 (0.44) SMN1; SMN2F10RAB9AMAPK1TP53
SCHEMBL13665010 0.89 SMN1; SMN2 (0.55) SMN1; SMN2F10HPGDMAPK1TP53
SCHEMBL13290953 0.88 SMN1; SMN2 (0.43) SMN1; SMN2F10RAB9AMAPK1TP53
SCHEMBL13290959 0.87 SMN1; SMN2 (0.43) SMN1; SMN2F10HPGDRAB9AMAPK1
SCHEMBL13290946 0.87 SMN1; SMN2 (0.43) SMN1; SMN2F10RAB9AMAPK1TP53
SCHEMBL2952052 0.86 F10 (0.42) SMN1; SMN2F10RAB9AMAPK1TP53
SCHEMBL2952053 0.86 F10 (0.42) SMN1; SMN2F10RAB9AMAPK1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156803-A1 Condensed furan compounds F2, F12, F11 SMN1; SMN2 4447/4885F10 4/4885HPGD 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback